MedTrace Logo

Pharmacotherapy Personalization of Cancer Patients

NCT04866498 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2021-04-29

No results posted yet for this study

Summary

Treatment personalization could ensure better outcome than standard procedures. It is particularly important in intensive care units where patients received many drugs and procedures. Their health status can change very fast. The oncologic patients treated in intensive care units are a special group of patients. Factors related to cancer influence extra their health status. The aim of this study is population pharmacokinetic-pharmacodynamic analysis drugs that are routinely used during an analgosedation in ICU oncologic patients. Analgosedation is monitored by drugs plasma concentration, the depth of sedation (bispectral index) and vital parameters like: systolic and diastolic blood pressure, mean arterial pressure, heart rate. Moreover, the TNM Staging System, biochemical parameters, The American Society of Anesthesiologists (ASA) physical status classification will be checked like potential factors influencing on pharmacokinetics and pharmacodynamics drugs used in the study.

Conditions

  • Head and Neck Neoplasms
  • Oncologic Patients

Interventions

DRUG

Infusion Intravenous

Sponsors & Collaborators

  • The Greater Poland Cancer Centre

    collaborator OTHER

  • Medical University of Gdansk

    collaborator OTHER

  • Poznan University of Medical Sciences

    lead OTHER

Principal Investigators

  • Agnieszka Bienert, MSC, PhD · Poznan University of Medical Sciences

  • Edmund Grzeskowiak, MSC, PhD · Poznan University of Medical Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-01
Primary Completion
2019-06-30
Completion
2021-03-31

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04866498 on ClinicalTrials.gov